1 October 2021 - The federal government will for the first time share the costs of an alternative treatment for two common but debilitating illnesses that impact more than 175,000 Aussies.
Rinvoq has been listed on the Pharmaceutical Benefits Scheme for the first time, for eligible adults with severe active cases of psoriatic arthritis or ankylosing spondylitis.